Business
Grant of Options
Grant of Options.
About this update from Oxford Biodynamics Plc
[{"type":"text","content":"\n\n \n \n Oxford BioDynamics Plc\n(\"OBD\" or the \"Company\" and, together with its subsidiaries, the \"Group\")\n \nPDMR Dealing / Grant of Share Options\n \n21 June 2024 - Oxford BioDynamics Plc (AIM: OBD), a biotechnology company developing precision medicine tests based on the EpiSwitch® 3D genomics platform, announces that it has granted a total of 10,665,020 options over its ordinary shares of 1 pence each (\"Ordinary Shares\"), to certain Group employees, including 10,150,020 options to Chief Executive Officer, Dr Jon Burrows (\"the Grant of Options\"). The options were granted under the Company's 2016 Employee Share Option Plan with an exercise price of 9p per share.\n \nOne-third of the options granted to Dr Burrows will vest and become exercisable on each of 23 March 2025, 23 March 2026 and 23 March 2027. Vested options will remain exercisable up to and including the tenth anniversary of the date of grant.\n \nFollowing this grant, Dr Jon Burrows, holds options over Ordinary Shares and is interested in Ordinary Shares as follows:\n \n\n\n\n\n\n\n\nTotal number of options over Ordinary Shares\n\n\nOrdinary Shares held\n\n\n\n\nNumber\n\n\n% of current issued share capital\n\n\n\n\nJon Burrows\n\n\n12,773,734\n\n\n1,088,888\n\n\n0.35%\n\n\n\n\n \nThe Grant of Options constitutes a related party transaction pursuant to AIM Rule 13. The independent directors of the Company consider, having consulted with the Company's nominated adviser, Shore Capital and Corporate Limited, that the Grant of Options is fair and reasonable insofar as the Company's shareholders are concerned.\n \nThe information set out below is provided in accordance with the requirements of the UK Market Abuse Regulation.\n \n\n\n\n\n1\n\n\nDetails of the person discharging managerial responsibilities/person closely associated\n\n\n\n\na)\n\n\nName\n\n\nJon Burrows\n\n\n\n\n2\n\n\nRea...